All News
Filter News
Found 297 articles
-
Atavistik Bio Appoints Bryan Stuart as Chief Executive Officer
7/17/2023
Atavistik Bio today announced the appointment of Bryan Stuart as Chief Executive Officer (CEO) and a Director on the company’s Board.
-
Rarebase Announces Promotion of Chris Moxham to President
7/13/2023
Rarebase today announced the promotion of Chris Moxham, Ph.D., to the newly created role of President effective immediately.
-
Fulcrum Therapeutics Signs Exclusive Global License Agreement in Rare Hematology CAMP4 Therapeutics grants exclusive rights to advance novel therapies for Diamond-Blackfan Anemia
7/10/2023
Fulcrum Therapeutics, Inc. today announced that it has entered into a worldwide, exclusive license agreement with CAMP4 Therapeutics Corp., whereby Fulcrum will advance the discovery, development, and commercialization of novel therapeutic agents against an undisclosed target for the potential treatment of Diamond-Blackfan Anemia (DBA).
-
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 07, 2023
7/7/2023
Fulcrum Therapeutics, Inc.® announced that the Company granted non-statutory stock options to a new employee.
-
Bionomics Announces Key Leadership Updates to Drive U.S.-Focused Transformation and Next Stage of Strategic Growth
7/3/2023
Bionomics Limited announced key leadership updates to drive its ongoing transformation to a U.S.-focused company, streamline its allocation of capital, and support its next stage of strategic growth.
-
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 09, 2023
6/9/2023
Fulcrum Therapeutics, Inc.®, a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced that the Company granted non-statutory stock options to new employees.
-
Fulcrum Therapeutics Appoints Alex C. Sapir Chief Executive Officer
5/15/2023
Fulcrum Therapeutics, Inc.®, a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced the appointment of Alex C. Sapir as chief executive officer and president, effective July 1st, 2023.
-
OMass Therapeutics Announces Appointment of New Board Chair and Series B Extension
5/15/2023
OMass Therapeutics announces the appointment of Jim Geraghty as chairman of its board of directors and an additional investment of £10 million from new investor British Patient Capital in a Series B extension, bringing the total raised in this round to £85.5 million.
-
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for the First Quarter 2023
5/15/2023
Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today reported financial results for the first quarter 2023 and provided a business update.
-
Fulcrum Therapeutics to Host First Quarter 2023 Financial Results Conference Call and Webcast on Monday, May 15, 2023, at 8:00 a.m. ET
5/8/2023
Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC) today announced that its first quarter 2023 financial results will be released on Monday, May 15, 2023 before the U.S. financial markets open.
-
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 5, 2023
5/5/2023
Fulcrum Therapeutics, Inc. today announced that the Company granted non-statutory stock options to new employees.
-
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 7, 2023
4/7/2023
Fulcrum Therapeutics, Inc. today announced that the Company granted non-statutory stock options to new employees.
-
Fulcrum Therapeutics Announces CFO Resignation
4/5/2023
Fulcrum Therapeutics, Inc.®, a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced that Esther Rajavelu has resigned from her position as chief financial officer and treasurer effective April 21, 2023.
-
Bicycle Therapeutics Enhances Leadership Team with Key Appointments
4/3/2023
Bicycle Therapeutics plc, a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide technology, announced the appointment of Santiago Arroyo, M.D., Ph.D., as Chief Development Officer, effective March 31.
-
Harbour BioMed Reports Full Year 2022 Financial Results
4/3/2023
Harbour BioMed, a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immune-oncology and immunology, released annual results of full year 2022.
-
In an earnings call Wednesday, bluebird bio revealed it is unlikely to meet its first-quarter goal to submit a Biologics License Application for sickle cell disease (SCD) gene therapy lovo-cel.
-
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 10, 2023
3/10/2023
Fulcrum Therapeutics, Inc.® announced that the Company granted non-statutory stock options to new employees.
-
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for the Fourth Quarter and Full Year 2022
3/9/2023
Fulcrum Therapeutics, Inc. today reported financial results for the fourth quarter and full year 2022 and provided a business update, including on FTX-6058.
-
Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on Thursday, March 9, 2023, at 8:00 a.m. ET
3/6/2023
Fulcrum Therapeutics, Inc. today announced that its fourth quarter and full year 2022 financial results will be released on Thursday, March 9, 2023 before the U.S. financial markets open.
-
The hits kept coming for the sickle cell disease space last week as the FDA placed a full clinical hold on Fulcrum Therapeutics’ Investigational New Drug application FTX-6058.